ETF Managers Group, LLC Assembly Biosciences, Inc. Transaction History

ETF Managers Group, LLC

$2.78 Billion
Q1 2023

A detailed history of ETF Managers Group, LLC transactions in Assembly Biosciences, Inc. stock. As of the latest transaction made, ETF Managers Group, LLC holds 16,315 shares of ASMB stock, worth $223,841. This represents 0.0% of its overall portfolio holdings.

Number of Shares

16,315

Previous 12,161 34.16%

Holding current value

$223,841

Previous $15,000 13.33%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 17, 2023	BUY	$0.8 - $1.74 $3,323 - $7,227	4,154 Added 34.16%	16,315 $13,000
Q4 2022 Mar 23, 2023	SELL	$1.09 - $1.52 $2,323 - $3,240	-2,132 Reduced 14.92%	12,161 $15,000
Q3 2022 Nov 14, 2022	SELL	$1.7 - $2.34 $1,598 - $2,199	-940 Reduced 6.17%	14,293 $23,000
Q2 2022 Aug 15, 2022	BUY	$1.35 - $2.29 $965 - $1,637	715 Added 4.92%	15,233 $32,000
Q1 2022 May 13, 2022	BUY	$1.46 - $2.45 $71 - $120	49 Added 0.34%	14,518 $30,000

Q4 2021 Feb 14, 2022	SELL	$2.13 - $3.46 $4,157 - $6,753	-1,952 Reduced 11.89%	14,469 $33,000
Q3 2021 Nov 15, 2021	BUY	$3.14 - $3.9 $14,359 - $17,834	4,573 Added 38.6%	16,421 $57,000
Q2 2021 Aug 16, 2021	BUY	$3.8 - $4.56 $463 - $556	122 Added 1.04%	11,848 $46,000
Q1 2021 May 17, 2021	SELL	$4.33 - $6.63 $18,774 - $28,747	-4,336 Reduced 27.0%	11,726 $53,000
Q4 2020 Feb 16, 2021	SELL	$4.87 - $17.29 $11,361 - $40,337	-2,333 Reduced 12.68%	16,062 $98,000
Q3 2020 Nov 16, 2020	BUY	$15.08 - $27.04 $125,616 - $225,243	8,330 Added 82.76%	18,395 $299,000
Q2 2020 Aug 14, 2020	BUY	$14.57 - $23.96 $146,647 - $241,157	10,065 New	10,065 $236,000

Others Institutions Holding ASMB

# of Institutions

Shares Held

16.3K

Call Options Held

Put Options Held

View Full List

About ASSEMBLY BIOSCIENCES, INC.

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $665M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

More about ASMB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of ETF Managers Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on ETF Managers Group, LLC with notifications on news.

Account

ETF Managers Group, LLC Assembly Biosciences, Inc. Transaction History